Tim T. Guilliams

Park House, Castle Park
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

A novel combination treatment for fragile X syndrome predicted using computational methods.

A novel combination treatment for fragile X syndrome predicted using computational methods.

Journal: Brain communications

Published: June 12, 2023

The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force.

The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force.

Journal: Orphanet journal of rare diseases

Published: April 12, 2019

Drug repurposing: progress, challenges and recommendations.

Drug repurposing: progress, challenges and recommendations.

Journal: Nature reviews. Drug discovery

Published: October 13, 2018

Understanding and predicting disease relationships through similarity fusion.

Understanding and predicting disease relationships through similarity fusion.

Journal: Bioinformatics (Oxford, England)

Published: February 23, 2018

The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5.

The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5.

Journal: Human molecular genetics

Published: February 21, 2018

Repurposing available drugs for neurodevelopmental disorders: The fragile X experience.

Repurposing available drugs for neurodevelopmental disorders: The fragile X experience.

Journal: Neuropharmacology

Published: January 04, 2018

Exploring the role of post-translational modifications in regulating α-synuclein interactions by studying the effects of phosphorylation on nanobody binding.

Exploring the role of post-translational modifications in regulating α-synuclein interactions by studying the effects of phosphorylation on nanobody binding.

Journal: Protein science : a publication of the Protein Society

Published: December 30, 2017

Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species.

Nanobodies raised against monomeric ɑ-synuclein inhibit fibril formation and destabilize toxic oligomeric species.

Journal: BMC biology

Published: April 11, 2017

Structural Effects of Two Camelid Nanobodies Directed to Distinct C-Terminal Epitopes on α-Synuclein.

Structural Effects of Two Camelid Nanobodies Directed to Distinct C-Terminal Epitopes on α-Synuclein.

Journal: Biochemistry

Published: April 21, 2016

Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation.

Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 10, 2015

Identifying the science and technology dimensions of emerging public policy issues through horizon scanning.

Identifying the science and technology dimensions of emerging public policy issues through horizon scanning.

Journal: PloS one

Published: November 11, 2013

Preconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation.

Preconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation.

Journal: PloS one

Published: June 18, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026